Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 13/20 | 0.52 |
| ▸ | PARP6 | Q2NL67 | 4/20 | 0.51 |
| ▸ | PARP3 | Q9Y6F1 | 4/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394532 | 1.00 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL25093486 | 0.89 | PARP1 (0.55) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL30064351 | 0.88 | PARP1 (0.50) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL22912684 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL22912763 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL29396334 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL29396473 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL25606984 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL29394287 | 0.84 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL28702467 | 0.84 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101892-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025040767-A1 | 2-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1,3,5-TRIAZINE DERIVATIVES AS KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2025-02-27 | — | — | WO | disclosed |
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-118139862-A | Nitrogen-containing heterocyclic compound and medical application thereof | 中国医药研究开发中心有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118119629-A | Nitrogen-containing heterocyclic compound and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240132522-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-4334314-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4328224-A1 | PARP INHIBITOR CONTAINING PIPERAZINE STRUCTURE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328225-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-116143776-A | PARP1 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023046158-A1 | AZAQUINOLINONE COMPOUND AND MEDICAL USE THEREOF | 张文燕 | 2023-03-30 | — | — | WO | disclosed |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-12-01 | — | — | US | disclosed |
| WO-2022235585-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-115260189-A | Synthetic method of 3-ethyl-7- (hydroxymethyl) -1,5-naphthyridin-2 (1H) -ketone | 爱斯特（成都）生物制药股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022222995-A1 | PICOLINAMIDE COMPOUND | 南京明德新药研发有限公司 | 2022-10-27 | — | — | WO | disclosed |
| US-11325906-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2022-05-10 | — | — | US | disclosed |
| WO-2022074617-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20210040084-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| WO-2021013735-A1 | PARP1 INHIBITORS | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885PARP2 1805/4885PARP6 1162/4885 |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | PARP1 3839/4885PARP2 4136/4885PARP6 3330/4885 |
| US-20210040084-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | PARP1 399/4885PARP2 586/4885PARP6 600/4885 |
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | PARP1 1119/4885PARP2 2032/4885PARP6 965/4885 |
| US-20240132522-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885PARP2 4/4885PARP6 10/4885 |
| US-11325906-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | PARP1 399/4885PARP2 586/4885PARP6 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.